Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.61 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.41 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19770203 | 1.00 | CHRM3 (0.61) | CHRM3DRD2DRD4ACACBACACA | |
| SCHEMBL19770200 | 0.91 | CHRM3 (0.67) | CHRM3DRD2DRD4ADRB2ACHE | |
| SCHEMBL19782567 | 0.91 | CHRM3 (0.67) | CHRM3DRD2DRD4ADRB2ACHE | |
| SCHEMBL19782485 | 0.84 | DRD2 (0.44) | CHRM3DRD2DRD4ACACBACACA | |
| SCHEMBL17985864 | 0.81 | CHRM3 (0.62) | CHRM3DRD2DRD4ADRB2 | |
| SCHEMBL17985861 | 0.81 | CHRM3 (0.62) | CHRM3DRD2DRD4ADRB2 | |
| SCHEMBL19782517 | 0.79 | CHRM3 (0.59) | CHRM3ADRB2ACHEBCHEMAOB | |
| SCHEMBL19770191 | 0.79 | CHRM3 (0.68) | CHRM3DRD2DRD4ADRB2ACHE | |
| SCHEMBL19770175 | 0.77 | CHRM3 (0.82) | CHRM3DRD2DRD4ACHEBCHE | |
| SCHEMBL17985973 | 0.76 | CHRM3 (0.83) | CHRM3DRD2DRD4ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-02-05 | — | — | US | disclosed |
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016267-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | CHRM3 13/4885DRD2 373/4885DRD4 1506/4885 |
| US-10196386-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | CHRM3 13/4885DRD2 373/4885DRD4 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.